Influence of CYP3A5 and Drug Transporter Polymorphisms on Imatinib Trough Concentration and Clinical Response Among Patients With Chronic Phase Chronic Myeloid Leukemia

Journal of Human Genetics - United Kingdom
doi 10.1038/jhg.2010.98
Full Text
Abstract

Available in full text

Categories
Genetics
Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Therapeutic Drug Monitoring of Imatinib for Chronic Myeloid Leukemia Patients

2012English

Therapeutic Drug Monitoring of Imatinib, Nilotinib, and Dasatinib for Patients With Chronic Myeloid Leukemia

Biological and Pharmaceutical Bulletin
MedicinePharmacologyPharmaceutical Science
2015English

Micro-Rna Response to Imatinib Mesylate in Patients With Chronic Myeloid Leukemia

Haematologica
Hematology
2010English

The Clinical Relevance of Imatinib Plasma Trough Concentrations in Chronic Myeloid Leukemia. A Belgian Study

Clinical Biochemistry
MedicineClinical Biochemistry
2017English

Imatinib and Plasmacytoid Dendritic Cell Function in Patients With Chronic Myeloid Leukemia

Blood
BiochemistryImmunologyCell BiologyHematology
2004English

Imatinib Pharmacokinetics and Its Correlation With Response and Safety in Chronic-Phase Chronic Myeloid Leukemia: A Subanalysis of the IRIS Study

Blood
BiochemistryImmunologyCell BiologyHematology
2008English

Somatic Mutations Identified at Diagnosis by Exome Sequencing Can Predict Response to Imatinib in Chronic Phase Chronic Myeloid Leukemia Patients

American Journal of Hematology
Hematology
2017English

Cost-Effectiveness of Dasatinib and Nilotinib for Imatinib-Resistant or -Intolerant Chronic Phase Chronic Myeloid Leukemia

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2011English

Polycomb Genes Are Associated With Response to Imatinib in Chronic Myeloid Leukemia

Epigenomics
Cancer ResearchGenetics
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy